Pazopanib Tablet, Film Coated
Product Images NDC 63304-116

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Pazopanib (NDC 63304-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-pazopanib-200 mg-label 1 (Spl Pazopanib 200mg Label1)

Pazopanib Tablets 200 mg film-coated oral tablets packaging label by Sun Pharmaceutical Industries, Inc. The label includes the NDC 63304-116, dosage information, and a count of 30 tablets per package. It warns to dispense with Medication Guide and notes the pharmaceutical form and storage instructions.*

FDA Label Image

Spl-pazopanib-200 mg-label 2 (Spl Pazopanib 200mg Label2)

Pazopanib 200 mg film-coated tablets label for oral use, manufactured by Sun Pharmaceutical Industries, Inc. The label includes NDC 63304-116-13 and states each tablet contains 216.7 mg of pazopanib hydrochloride equivalent to 200 mg of pazopanib free base. The package contains 120 tablets and specifies prescription dispensing with a medication guide. Includes a barcode and storage instructions.*

FDA Label Image

Spl-pazopanib-figure 1 (Spl Pazopanib Figure1)

A Kaplan-Meier survival plot comparing progression-free proportions over months for Pazopanib and Placebo groups. The x-axis represents months, the y-axis shows the proportion progression-free. Pazopanib group (N=290) shows longer median progression-free survival (9.2 months) than Placebo (N=145, 4.2 months). Hazard ratio, confidence interval, and p-value are included.*

FDA Label Image

Spl-pazopanib-figure2 (Spl Pazopanib Figure2)

A survival curve graph comparing the proportion progression-free over time in months between pazopanib and placebo groups. The curve shows a higher proportion progression-free for pazopanib compared to placebo, with median times of 4.6 months and 1.5 months respectively, including hazard ratio and statistical values.*

FDA Label Image

Spl-pazopanib-structure (Spl Pazopanib Structure)

Chemical structure diagram of Pazopanib, showing its molecular framework with labeled functional groups and atoms, including a hydrochloride (HCl) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.